BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
基本信息
- 批准号:8786056
- 负责人:
- 金额:$ 40.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-01-01 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAntiviral AgentsApoptosisApoptoticB lymphoid malignancyBH3 DomainBindingBiologicalBiological AssayCCR8 geneCell SurvivalCellsCoupledCustomDefense MechanismsDetectionDevelopmentDiseaseEndothelial CellsFutureG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGTP-Binding ProteinsHIVHealthHomologous GeneHuman Herpesvirus 8ImmuneIn VitroIndividualInfectionKaposi SarcomaLaboratoriesLeadLinkLyticLytic PhaseMapsMediatingMediator of activation proteinMethodsModelingMulticentric Angiofollicular Lymphoid HyperplasiaNoxaePathologyPathway interactionsPeptidesPhage DisplayPharmaceutical PreparationsPhosphorylationPhysiologic pulsePost-Translational RegulationProcessProductionProtein Binding DomainProteinsPublic HealthReagentReceptor SignalingRegulationReportingResearchRoleSignal PathwaySignal TransductionStressSystemTestingTherapeuticTranscriptional RegulationUbiquitinationVariantViralViral Load resultViral PhysiologyViral ProteinsVirusVirus DiseasesVirus InhibitorsVirus Replicationbasechemokinechemokine receptorco-infectiondisorder preventiongenetic resistanceinhibitor/antagonistlytic replicationnovelpreventprimary effusion lymphomaprotein functionresearch studysmall hairpin RNAsmall moleculeviral interferon regulatory factorviral interferon regulatory factor-1
项目摘要
DESCRIPTION (provided by applicant): Human herpesvirus 8 (HHV-8) is associated with endothelial Kaposi's sarcoma (KS) and B cell malignancies primary effusion lymphoma and multicentric Castleman's disease, all of which occur predominantly in the context of HIV coinfection. Both latent and lytic gene products are believed to contribute to these pathologies, and productive replication and increased viral loads are associated with KS. Understanding the processes required for successful lytic replication will provide opportunities for targeting essential viral functions to block virus replication and thereby treat or prevent HHV-8 associated disease. Key to replication by HHV-8 and other viruses are viral mechanisms that limit stress-induced apoptotic signaling that serves as an innate defense mechanism against virus infection. HHV-8 encodes several proteins that inhibit such pro-apoptotic pathways. These proteins include viral interferon regulatory factor-1 (vIRF-1), viral G protein coupled receptor (vGPCR), and viral chemokines vCCL-1 and vCCL-2, all of which have been demonstrated to both inhibit apoptosis and be required for efficient virus replication. This laboratory has identified inhibitor interactions of vIRF-1 with replication-induced pro-apoptotic BH3-only proteins (BOPs) Bim and Bid and revealed the critical importance of controlling these proteins for efficient virus replicaton to occur. Suppression of Bim or Bid expression via transduced shRNAs leads to very significant increases in virus replication, and disruption of vIRF-1:BOP interactions inhibits virus production
and promotes apoptosis in lytically infected cells. In addition to Bim and Bid, vIRF-1 targets other BOPs (Bik, Bmf, Hrk, Noxa), via their functional BH3 domains, indicating the biological importance of these BOPs also and the need to inhibit their activities during lytic replication. Furthermore, the viral chemokine receptor (vGPCR) and CCR8 agonists vCCL-1 and vCCL-2 activate signaling pathways that lead to suppression of Bim expression. Thus, chemokine receptor signaling is likely to enhance HHV-8 productive replication in part via BOP regulation. This application proposes to: (1) elucidate the mechanisms of vGPCR and vCCL suppression of Bim, an identified major inhibitor of HHV-8 replication; (2) identify peptide and pharmacological inhibitors of vIRF-1:BOP interactions to specifically inhibit this mechanism of BOP regulation; (3)
determine the antiviral activities of lytic cycle-induced BOPs and the individual and combined contributions, via BOP control, of vCCLs, vGPCR, and vIRF-1 to HHV- 8 productive replication. The project comprises a focused analysis of BOP function and targeting by vCCLs, vGPCR and vIRF-1 during HHV-8 lytic replication and assessment of inhibitory reagents and methods that could potentially be developed for antiviral purposes.
描述(由申请方提供):人疱疹病毒8型(HHV-8)与内皮卡波西肉瘤(KS)和B细胞恶性肿瘤、原发性渗出性淋巴瘤和多中心Castleman病相关,所有这些疾病主要发生在HIV合并感染的情况下。潜伏和裂解基因产物被认为有助于这些病理学,并且生产性复制和增加的病毒载量与KS相关。了解成功裂解复制所需的过程将为靶向基本病毒功能以阻断病毒复制提供机会,从而治疗或预防HHV-8相关疾病。HHV-8和其他病毒复制的关键是限制应激诱导的细胞凋亡信号传导的病毒机制,该信号传导作为针对病毒感染的先天防御机制。HHV-8编码几种抑制这种促凋亡途径的蛋白质。这些蛋白质包括病毒干扰素调节因子-I(vIRF-1)、病毒G蛋白偶联受体(vGPCR)和病毒趋化因子vCCL-1和vCCL-2,所有这些蛋白质都已被证明既抑制细胞凋亡又是有效病毒复制所需的。该实验室已经鉴定了vIRF-1与复制诱导的促凋亡BH 3-only蛋白(BOP)Bim和Bid的抑制剂相互作用,并揭示了控制这些蛋白对有效病毒复制发生的至关重要性。通过转导的shRNA抑制Bim或Bid表达导致病毒复制非常显著的增加,并且破坏vIRF-1:BOP相互作用抑制病毒产生
并促进裂解感染细胞的凋亡。除了Bim和Bid之外,vIRF-1通过其功能性BH 3结构域靶向其他BOP(Bik、Bmf、Hrk、Noxa),这也表明这些BOP的生物学重要性以及在裂解复制期间抑制其活性的需要。此外,病毒趋化因子受体(vGPCR)和CCR 8激动剂vCCL-1和vCCL-2激活导致Bim表达抑制的信号传导途径。因此,趋化因子受体信号可能部分通过BOP调节来增强HHV-8的生产性复制。本申请建议:(1)阐明Bim(一种已鉴定的HHV-8复制的主要抑制剂)的vGPCR和vCCL抑制机制;(2)鉴定vIRF-1:BOP相互作用的肽和药理学抑制剂,以特异性抑制BOP调节机制;(3)
确定裂解周期诱导的BOP的抗病毒活性以及vCCL、vGPCR和vIRF-1通过BOP对照对HHV- 8生产性复制的单独和组合贡献。该项目包括在HHV-8裂解复制期间重点分析BOP功能和vCCL,vGPCR和vIRF-1的靶向,并评估可能开发用于抗病毒目的的抑制试剂和方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Nicholas其他文献
John Nicholas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Nicholas', 18)}}的其他基金
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
- 批准号:
8994365 - 财政年份:2015
- 资助金额:
$ 40.5万 - 项目类别:
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
- 批准号:
9085244 - 财政年份:2015
- 资助金额:
$ 40.5万 - 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
- 批准号:
8595304 - 财政年份:2013
- 资助金额:
$ 40.5万 - 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
- 批准号:
8467210 - 财政年份:2013
- 资助金额:
$ 40.5万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 40.5万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 40.5万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别: